| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2011.38.0915 |
| P698 | PubMed publication ID | 22473155 |
| P50 | author | Olav Dahl | Q16188074 |
| Bengt Glimelius | Q30830855 | ||
| Per Pfeiffer | Q56839877 | ||
| Thoralf Christoffersen | Q125330474 | ||
| Eva Hofsli | Q125330611 | ||
| Tone Fokstuen | Q125331046 | ||
| P2093 | author name string | Flemming Hansen | |
| Nina Keldsen | |||
| Eva Skovlund | |||
| Olav Dajani | |||
| Halfdan Sorbye | |||
| Tone Ikdahl | |||
| Kjell Magne Tveit | |||
| Anders Johnsson | |||
| Hans Starkhammar | |||
| Fridbjorn Sigurdsson | |||
| Anne Berit Erdal | |||
| Elin Kure | |||
| Elke Birkemeyer | |||
| Mette Karen Yilmaz | |||
| Seppo Pyrhonen | |||
| Tormod Guren | |||
| P433 | issue | 15 | |
| P921 | main subject | colorectal cancer | Q188874 |
| fluorouracil | Q238512 | ||
| cetuximab | Q420296 | ||
| oxaliplatin | Q422327 | ||
| colorectal carcinoma | Q25493920 | ||
| phase III clinical trial | Q42824827 | ||
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 1755-1762 | |
| P577 | publication date | 2012-04-02 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study | |
| P478 | volume | 30 |
| Q36211003 | 2011 update in gastrointestinal cancer therapeutics |
| Q94546948 | A Retrospective Exploration of Targeted Maintenance Therapy in Advanced Colorectal Cancer: Based on the Background of Chinese Patient Assistance Program |
| Q33671792 | A Strategy to Delay the Development of Cisplatin Resistance by Maintaining a Certain Amount of Cisplatin-Sensitive Cells |
| Q36306554 | A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer |
| Q35921206 | A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification. |
| Q34580450 | A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial |
| Q41495258 | AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin |
| Q38229589 | Advances and new perspectives in the treatment of metastatic colon cancer |
| Q38943220 | Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen. |
| Q26748924 | Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer |
| Q36907279 | Alternate dosing of cetuximab for patients with metastatic colorectal cancer |
| Q37708019 | Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases. |
| Q38429462 | Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis |
| Q39347386 | BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies |
| Q97525759 | BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy |
| Q38238740 | Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. |
| Q38110024 | Biologic Agents in the Treatment of Colorectal Cancer: The Last Decade; the Lost Decade? |
| Q91754859 | Biomarker-guided therapy for colorectal cancer: strength in complexity |
| Q26766535 | Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS |
| Q37299578 | Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies |
| Q38099726 | Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial |
| Q33829760 | Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study |
| Q37204600 | Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model |
| Q37735615 | Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer |
| Q42596834 | Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial |
| Q37530472 | Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis. |
| Q26769958 | Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer |
| Q36344547 | Colorectal Cancer: Personalized Therapy |
| Q34352595 | Colorectal cancer in Chinese patients: current and emerging treatment options. |
| Q26768427 | Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances |
| Q90699218 | Comprehensive review of targeted therapy for colorectal cancer |
| Q34598203 | Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations |
| Q52842543 | Conceptual approaches to metastatic disease |
| Q38090584 | Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer |
| Q44365458 | Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer |
| Q92068909 | Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer |
| Q38933681 | Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study. |
| Q58589967 | Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin |
| Q35773077 | Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. |
| Q47369045 | Does the Addition of Biologic Agents to Chemotherapy in Patients with Unresectable Colorectal Cancer Metastases Result in a Higher Proportion of Patients Undergoing Resection? A Systematic Review and Meta-analysis |
| Q35746635 | Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature |
| Q38923998 | ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas. |
| Q38175833 | Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies |
| Q37005364 | Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis |
| Q26777704 | Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis |
| Q53159209 | Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials |
| Q39694235 | Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis |
| Q38155482 | Emerging treatments in recurrent and metastatic colorectal cancer. |
| Q38666172 | Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. |
| Q42696006 | Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies |
| Q36892840 | Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial |
| Q92185841 | Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer |
| Q37408810 | Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients |
| Q83801494 | Explaining the Unexplainable: EGFR Antibodies in Colorectal Cancer |
| Q91684535 | Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies |
| Q35587176 | Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing |
| Q33712230 | FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab |
| Q52666988 | FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis |
| Q38176601 | Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). |
| Q42218820 | FcγR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer |
| Q36368646 | Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial |
| Q38587633 | First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405. |
| Q38555200 | First-line chemotherapy for mCRC—a review and evidence-based algorithm. |
| Q90450020 | First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials |
| Q38234000 | From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors |
| Q37326863 | Future of targeted agents in metastatic colorectal cancer |
| Q47673133 | Gastrointestinal Malignancy: Genetic Implications to Clinical Applications |
| Q35934455 | Genetics, diagnosis and management of colorectal cancer (Review). |
| Q26739052 | Genomic diversity of colorectal cancer: Changing landscape and emerging targets |
| Q38245875 | Guidance on the management of diarrhoea during cancer chemotherapy |
| Q41946954 | Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement |
| Q92716717 | Hepatic metastasis from colorectal cancer |
| Q35677169 | High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort |
| Q38110319 | How Do We Optimally use Cetuximab in First-Line Treatment for Metastatic Colorectal Cancer? |
| Q27026516 | How to select the optimal treatment for first line metastatic colorectal cancer |
| Q92316369 | Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer |
| Q57800147 | Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis |
| Q36261279 | Inhibition of SALL4 suppresses carcinogenesis of colorectal cancer via regulating Gli1 expression |
| Q43090496 | Integrating anti-EGFR therapies in metastatic colorectal cancer |
| Q38197617 | Interleukin-13 and its receptors in colorectal cancer (Review). |
| Q37688887 | Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer |
| Q33576199 | Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial |
| Q92734257 | KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study |
| Q37495964 | KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting |
| Q36557853 | KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. |
| Q37385227 | KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer |
| Q44526398 | Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. |
| Q34483581 | Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab |
| Q89522232 | Lithium chloride increases sensitivity to photon irradiation treatment in primary mesenchymal colon cancer cells |
| Q35419309 | Liver-directed conversion therapy in metastatic colon cancer. |
| Q92915718 | Long-term quality of life after liver transplantation for non-resectable colorectal metastases confined to the liver |
| Q53666492 | Maintenance therapy following first-line chemotherapy in metastatic colorectal cancer: toxicity and efficacy-single-institution experience |
| Q38588218 | Maintenance therapy for colorectal cancer: which regimen and which patients? |
| Q27026129 | Management of locally advanced and metastatic colon cancer in elderly patients |
| Q55032398 | Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). |
| Q36871770 | Management of potentially resectable colorectal cancer liver metastases |
| Q24598640 | Markers of resistance to anti-EGFR therapy in colorectal cancer |
| Q28074073 | Mechanisms of resistance to anti-EGFR therapy in colorectal cancer |
| Q37362955 | Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer |
| Q36838134 | Modern prospection for hepatic arterial infusion chemotherapy in malignancies with liver metastases |
| Q36813582 | Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. |
| Q91599765 | Molecular Profiles Guide Colorectal Cancer Treatment |
| Q41091941 | Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience |
| Q33779859 | Multidisciplinary approach of colorectal cancer liver metastases |
| Q28069575 | Multisciplinary management of patients with liver metastasis from colorectal cancer |
| Q92938243 | Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer |
| Q26796348 | New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? |
| Q34506141 | No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis |
| Q53108104 | Oligometastasized stage IV colorectal cancer : Surgical resection and local ablative procedures |
| Q38684918 | Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis |
| Q91831006 | Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond |
| Q36732725 | Outcomes in patients with obstructive jaundice from metastatic colorectal cancer and implications for management |
| Q28543278 | PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis |
| Q40126967 | Palliative care needs in hospitalized cancer patients: a 5-year follow-up study. |
| Q36977022 | Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial |
| Q38175030 | Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. |
| Q47954868 | Personalised cancer management: closer, but not here yet |
| Q34725699 | Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors |
| Q37548804 | Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study |
| Q41134824 | Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment |
| Q38271031 | Pragmatic issues in biomarker evaluation for targeted therapies in cancer |
| Q26795558 | Precision medicine in colorectal cancer: the molecular profile alters treatment strategies |
| Q26738655 | Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options |
| Q37697540 | Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. |
| Q51044379 | Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti‐epidermal growth factor receptor monoclonal antibodies: A meta‐analysis |
| Q33895573 | Primary and acquired resistance to biologic therapies in gastrointestinal cancers |
| Q38014668 | Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations |
| Q50973552 | Prognostic factors for overall survival in metastatic colorectal cancer using a stop-and-go FLIRI-based treatment strategy |
| Q89001815 | Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome |
| Q51066147 | Prognostic value of treatment-related factors in metastatic colorectal cancer using a stop-and-go strategy |
| Q91809153 | Promising Colorectal Cancer Biomarkers for Precision Prevention and Therapy |
| Q50977507 | Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis |
| Q28074175 | RAS and BRAF in metastatic colorectal cancer management |
| Q34650256 | Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases |
| Q33862425 | Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy |
| Q38163598 | Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q48226075 | Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial. |
| Q36895532 | Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer |
| Q37708010 | Role of cetuximab in first-line treatment of metastatic colorectal cancer |
| Q38104294 | Role of targeted agents in metastatic colorectal cancer. |
| Q28068817 | Role of targeted therapy in metastatic colorectal cancer |
| Q36194219 | S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial |
| Q33403790 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial |
| Q45204578 | Second‐line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild‐type KRAS |
| Q34894115 | Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX s |
| Q37602729 | Sequencing of treatment in metastatic colorectal cancer: where to fit the target |
| Q28088693 | Standard chemotherapy with cetuximab for treatment of colorectal cancer |
| Q48512300 | Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer |
| Q35069535 | Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis |
| Q39542406 | Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer |
| Q39146859 | Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells |
| Q61867795 | Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial |
| Q54114270 | Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer |
| Q37644878 | TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer |
| Q30862367 | Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data |
| Q38096413 | Targeting Mechanisms of Resistance to Anti-EGF Receptor Therapy in KRAS Wild-Type Colorectal Cancer: The Path to More Personalized Medicine |
| Q35019470 | Targeting precision medicine toxicity: recent developments. |
| Q47141625 | The Developing Role of Anti-Epidermal Growth Factor Receptor Agents in the Treatment of Advanced or Metastatic Colorectal Cancer |
| Q52603506 | The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases. |
| Q38917649 | The Pharmacological Costs of Complete Liver Resections in Unselected Advanced Colorectal Cancer Patients: Focus on Targeted Agents. A Review of Randomized Clinical Trials |
| Q34776118 | The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis |
| Q34648886 | The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer |
| Q38755667 | The anti-oncogenic influence of ellagic acid on colon cancer cells in leptin-enriched microenvironment. |
| Q28066460 | The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care |
| Q37130603 | The role of personalized medicine in metastatic colorectal cancer: an evolving landscape |
| Q37015715 | The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers |
| Q26775522 | Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review |
| Q28071772 | Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence |
| Q26747335 | Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer |
| Q51030597 | Treatment of Metastatic Colon Cancer: “The Times They Are A-Changing” |
| Q47406196 | Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer |
| Q56932681 | Trial watch: Monoclonal antibodies in cancer therapy |
| Q87414311 | Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study |
| Q40996412 | Use and impact of intermittent versus continuous systemic treatment strategies in metastatic colorectal cancer in routine practice |
| Q36999699 | What is the optimal neo-adjuvant treatment for liver metastasis? |
| Q46225923 | Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody |
| Q89004316 | [Oligometastasized colorectal cancer-modern treatment strategies] |
| Q33773806 | miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan |
Search more.